Navigation Links
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2011 Results
Date:9/22/2011

790,916)Income tax benefit

--637,391998,408NET LOSS

$  (3,309,229)$ (4,236,381)$(12,815,929)$  (1,792,508)Basic and diluted net loss per common share

$
(0.09)$
(0.40)$
(0.64)$
(0.18)Weighted average number of common shares outstanding used in computing basic and diluted net loss per common share

34,900,59110,722,06120,084,0229,861,215PALATIN TECHNOLOGIES, INC.

and SubsidiaryConsolidated Balance Sheets(unaudited)June 30, 2011June 30, 2010ASSETSCurrent assets:  Cash and cash equivalents$
8,869,639$
5,405,430  Available-for-sale investments-3,462,189  Accounts receivable131,1492,879  Prepaid expenses and other current assets261,947393,313Total current assets19,262,7359,263,811Property and equipment, net1,305,3312,388,365Restricted cash350,000475,000Other assets254,787261,701Total assets$
21,172,853$
2,388,877LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:  Capital lease obligations$
34,923$
9,670  Accounts payable 496,908155,795  Accrued expenses1,854,0072,219,466  Accrued expenses374,094-  Unearned revenue46,105-Total current liabilities2,806,0372,394,931Capital lease obligations 42,18614,284Deferred rent132,855661,389Total liabilities2,981,0783,070,604Stockholders' equity:  Preferred stock of $0.01 par value – authorized 10,000,000 shares;Series A Convertible; issued and outstanding 4,997 shares as of June 30, 2011 and 2010, respectively5050  Common stock of $0.01 par value – authorized 100,000,000 shares; issued and outstanding 34,900,591 and 11,702,818 shares as of June 30, 2011 and 2010, respectively349,006117,028  Additional paid-in capital239,832,826218,236,723  Accumulated other comprehensive income-138,650  Accumulated deficit (221,990,107)(209,174,178)Total stockholders' equity18,191,7759,318,273Total liabilities and stockholders' equity$
21,172,853$
2,388,877
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
2. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
3. Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
4. Palatin Technologies Receives Notification Letter from NYSE Alternext US
5. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009
6. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US
7. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
8. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
9. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
10. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
11. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Dallas, TX, USA (PRWEB) , ... July 30, ... ... nano and microsystems, has appointed Francois Vieillard as Sales & Marketing Director. ... executive positions, Francois Vieillard will be responsible for reinforcing Tronics’ business development activities ...
(Date:7/30/2015)... , July 30, 2015 According ... Product (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, Toxicity ... Development, Preclinical, Clinical Trial), by End Users - Global ... is expected to reach USD 2,107.99 million by 2020 ... of 15.29%. Browse more than ...
(Date:7/30/2015)... , July 30, 2015   Aratana Therapeutics, ... therapeutics company focused on the licensing, development and ... today announced that its strategic partner VetStem Biopharma, ... confirmation study of AT-016, an adipose-derived allogeneic stem ... treatment of osteoarthritis pain in dogs. ...
(Date:7/30/2015)... globe, ISN improves the efficiency and effectiveness of contractor management systems. ISN,s online contractor ... in over 80 countries. ... ... Over 60,000 Worldwide Customers In More Than 80 Countries ... Dallas, TX , ISN has additional offices in Calgary , ...
Breaking Biology Technology:Tronics appoints Francois Vieillard as Sales and Marketing Director 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3
... , INCLINE VILLAGE, Nev., Oct. 28 PDL BioPharma, ... it has priced a $300 million securitization transaction intended ... royalties. , Upon closing of the transaction, which is ... will sell to QHP Royalty Sub LLC ("QHP"), a ...
... , MINNEAPOLIS, Oct. 28 Techne Corporation,s (Nasdaq: ... September 30, 2009 decreased 6.4% to $26.8 million or ... $.74 per diluted share for the quarter ended September ... mainly due to foreign currency fluctuations, decreased consolidated net ...
... ... of work in September, health care industry continued growing, adding 19,000 new jobs. But ... ... healthcare and related fields continued to grow, even as more Americans found themselves out of ...
Cached Biology Technology:PDL BioPharma Announces Pricing of $300,000,000 Securitization Transaction 2PDL BioPharma Announces Pricing of $300,000,000 Securitization Transaction 3Techne Corporation Releases Unaudited First Quarter Results For Fiscal Year 2010 2Techne Corporation Releases Unaudited First Quarter Results For Fiscal Year 2010 3Techne Corporation Releases Unaudited First Quarter Results For Fiscal Year 2010 4Techne Corporation Releases Unaudited First Quarter Results For Fiscal Year 2010 5Techne Corporation Releases Unaudited First Quarter Results For Fiscal Year 2010 6The MedZilla Report for September 2009 - Care Grows Again in September and - Surprisingly - Pharma Sales Jobs Up Too 2The MedZilla Report for September 2009 - Care Grows Again in September and - Surprisingly - Pharma Sales Jobs Up Too 3The MedZilla Report for September 2009 - Care Grows Again in September and - Surprisingly - Pharma Sales Jobs Up Too 4
(Date:7/30/2015)... MOUNTAIN VIEW, Calif. , July 30, 2015 ... products and services for gene function analysis and ... CRISPR Guide RNA (sgRNA) Knockout Library targeting all ... to specifically and permanently "knock out" a gene,s ... library provides a high throughput screening tool so ...
(Date:7/27/2015)... 2015   Zynx Health ™, the market ... solutions, today announced that its ZynxCarebook ™ ... Android smartphones and tablets. With this expansion, care ... use ZynxCarebook to securely exchange messages and share ... transitions to other care settings, and improve clinical ...
(Date:7/23/2015)... , July 23, 2015 Research ... addition of the "Global Outlook of the ... offering. The global biometrics market ... public and commercial applications owing to the uptake ... witness a transformation that enhances the growth of ...
Breaking Biology News(10 mins):CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3
... MA -- Using ultrasound waves, MIT engineers have found ... drugs, making transdermal drug delivery more efficient. This technology ... needle-free vaccinations, according to the researchers. "This could ... cortisol, for example systemic drugs and proteins such ...
... strides in identifying genes that lead to an increased ... a continuum of social deficits, communication difficulties and cognitive ... these genetic risk factors impact the brain,s structure and ... developed. This led researchers at UCLA ...
... FARMINGTON, Conn., Sept. 13, 2012 /PRNewswire-iReach/ -- Global ... time offer on personalized medicine, next generation sequencing ... Pacific, a bio/pharmaceutical and life sciences industry analyst ... http://photos.prnewswire.com/prnh/20120913/CG74123 ) Personalized Medicine: Companies, Trends ...
Cached Biology News:Getting (drugs) under your skin 2Getting (drugs) under your skin 3Study reveals how common gene mutation affects kids with autism spectrum disorders 2Study reveals how common gene mutation affects kids with autism spectrum disorders 3How to Differentiate Your Pharmaceutical Product in the Personalized Medicine Segment 2How to Differentiate Your Pharmaceutical Product in the Personalized Medicine Segment 3